- AbbVie reported a Q2 2026 performance beat driven by double-digit growth in Skyrizi, Rinvoq, and its neuroscience portfolio.
- The company lowered its full-year earnings guidance to account for its proposed acquisition of Apogee Therapeutics, which is expected to close in Q3.
- Management expects the Apogee transaction to contribute $0.14 of dilution to full-year earnings, while underlying business performance improves by $0.10.
- Humira sales fell 36.1% operationally due to biosimilar competition, a decline that was in line with management expectations.
Quotes
“AbbVie (ABBV) shares fell more than 4% in the early premarket trading on Friday after the Humira maker, with its Q2 2026 financials, lowered its full-year earnings outlook to reflect its proposed acquisition of inflammatory drug developer Apogee Therapeutics”
“The acquisition of Apogee Therapeutics is a strategic move to bolster the immunology pipeline with long-acting biologics for the 2030s and beyond.”